Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI)
Status:
Not yet recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2 study to determine the safety and efficacy of allogeneic (third party),
bone-marrow derived mesenchymal stromal cells (MSCs) for the treatment of Osteogenesis
Imperfecta (OI) Type 3. It will evaluate this by looking at whether there are treatment
related infusion reactions, and assessing linear growth rates and bone health, both of which
are impaired in patients ages 3-10 with Osteogenesis Imperfecta Type 3. This is a single-site
non-randomized clinical trial, that will take place at Children's Healthcare of Atlanta
(CHOA) at Egleston and Emory Children's Center.